- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Qilu Pharmaceutical Co. Ltd.
BioCentury | Apr 21, 2023
Management Tracks
Allogene hires former Kite exec Moore
Plus: LianBio promotes Pascal to CCO and updates from Ocuphire and ImmVira
BioCentury | Dec 14, 2021
Product Development
Dec. 13 Quick Takes: Bellus headed for Phase III in chronic cough
Plus: Veru’s Entadfi approved, Brii asset on hold and updates from Arbutus, BrainStorm and Vaccitech
BioCentury | May 17, 2021
Management Tracks
Tousi promoted to chief commercial officer at Illumina; plus Kintor, Esperion, AffaMed, Escient and more
Susan Tousi was promoted to chief commercial officer at Illumina Inc. (NASDAQ:ILMN). Tousi joined the genome sequencing company in 2012 as VP of engineering, and was most recently SVP and chief
BioCentury | Mar 13, 2021
Translation in Brief
NIH identifies antisense oligos to treat progeria; plus epigenetic gene therapies for chronic pain and Cend’s pancreatic cancer therapy
BioCentury’s roundup of translational news
BioCentury | Feb 23, 2021
Product Development
Feb. 22 Quick Takes: Sanofi, J&J in COVID vaccine manufacturing deal; plus AZ, Regeneron-Sanofi, Incyte, Ascletis, Novo-Altasciences, Regor
Sanofi (Euronext:SAN; NASDAQ:SNY) will formulate and fill about 12 million doses per month of the single-shot COVID-19 vaccine from Johnson & Johnson (NYSE:JNJ) following authorization. The
BioCentury | Feb 16, 2021
Deals
Feb. 16 Quick Takes: Cytovia, Cellectis partner on TALEN-edited NK cells; plus Cend-Qilu, Iterion and Woodford
Cytovia Therapeutics Inc. and Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) began a strategic R&D collaboration to develop induced pluripotent stem cell-derived NK and CAR-NK cell therapies
BioCentury | Dec 10, 2020
Management Tracks
Ricks takes baton from Caforio at PhRMA; plus Bluestone joins Gilead board and Derrick Li returns to investment banking, joining Baird
Plus: management moves at Phagelux, Chiesi, Kanova and Oyster Point
BioCentury | Aug 1, 2020
Management Tracks
Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more
BioCentury | Apr 14, 2020
Management Tracks
Kelly joins CytoDyn as CMO amid COVID-19 trials; plus Antengene, Genetron, Bolt, BioSpecifics, CMAB and more
BioCentury | Aug 16, 2019
Product Development
China’s biosimilars in fast lane
Guest Commentary: Why China's biosimilars market could take off faster than the U.S.'s and Europe's
Items per page:
1 - 10 of 15